Zylox-Tonbridge Grants 400,000 Share Options Under 2025 Incentive Scheme

Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An announcement from Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) is now available. Zylox-Tonbridge Medical Technology has granted 400,000 share options under its 2025 Share Incentive Scheme to a single employee of the Group, with an exercise price of HK$23.472 per H share and a validity period extending to October 23, 2035. The options will vest in a single tranche on or before December 31, 2028, subject to minimum 12-month vesting, performance conditions tied to the relevant subsidiary’s financial results and the individual’s evaluation, and a lock-up that lasts until the earlier of three months after the Company holds 100% of Optimed Medizinische Instrumente GmbH or December 31, 2028, aligning employee incentives with operational performance and strategic integration of its German subsidiary. The most recent analyst rating on (HK:2190) stock is a Buy with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page. More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H Zylox-Tonbridge Medical Technology Co., Ltd. is a PRC-incorporated medical technology company listed in Hong Kong under stock code 2190. The Group develops and markets medical devices, with operations that include overseas subsidiaries such as Optimed Medizinische Instrumente GmbH, reflecting a focus on international expansion in the healthcare sector. YTD Price Performance: 2.34% Average Trading Volume: 749,030 Technical Sentiment Signal: Strong Buy Current Market Cap: HK$8.14B See more data about 2190 stock on TipRanks’ Stock Analysis page.